Ocular and Systemic Autoimmunity after Successful Tumor-Infiltrating Lymphocyte Immunotherapy for Recurrent, Metastatic Melanoma
- 1 May 2009
- journal article
- research article
- Published by Elsevier in Ophthalmology
- Vol. 116 (5) , 981-989.e1
- https://doi.org/10.1016/j.ophtha.2008.12.004
Abstract
No abstract availableFunding Information
- National Institutes of Health
- Cleveland Clinic Foundation
- Heed Ophthalmic Foundation
- National Eye Institute
- National Cancer Institute
This publication has 34 references indexed in Scilit:
- Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunityProceedings of the National Academy of Sciences, 2008
- Adoptive cell transfer: a clinical path to effective cancer immunotherapyNature Reviews Cancer, 2008
- Stage-IV Melanoma and Pulmonary Metastases: Factors Predictive of SurvivalAnnals of Surgical Oncology, 2007
- Cancer Regression in Patients After Transfer of Genetically Engineered LymphocytesScience, 2006
- The course of melanoma-associated vitiligo: report of a caseMelanoma Research, 2006
- Ocular Infiltrating CD4+T Cells from Patients with Vogt-Koyanagi-Harada Disease Recognize Human Melanocyte AntigensInvestigative Opthalmology & Visual Science, 2006
- Tumor Regression and Autoimmunity in Patients Treated With Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Interleukin 2: A Phase I/II StudyAnnals of Surgical Oncology, 2005
- Cytotoxic T Lymphocyte-Associated Antigen 4 Blockade in Patients with Metastatic MelanomaJournal of Immunotherapy, 2004
- Tumor Regression and Autoimmunity after Reversal of a Functionally Tolerant State of Self-reactive CD8+ T CellsThe Journal of Experimental Medicine, 2003
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000